Yahoo Finance11d
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired ...
TMCnet9d
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...
Rhythm Pharmaceuticals gets orphan drug designation for setmelanotide in Japan
Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for ...
Pharmabiz9d
Rhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in Japan
Rhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in Japan: Boston Friday, March 21, 2025, 16:00 Hrs [IST] Rhythm Pharmaceuticals, Inc ...
Nasdaq10d
Rhythm Pharmaceuticals Receives Orphan Drug Designation in Japan for Setmelanotide in Acquired Hypothalamic Obesity Treatment
Rhythm Pharmaceuticals, Inc. has announced that it received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for setmelanotide, a treatment aimed at acquired ...
Taiwan News10d
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...